Methylprednisolone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Methylprednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Methylprednisolone is a synthetic glucocorticoid; this Evidence Pack does not contain a documented original indication or Australian ARTG entry for the drug, so no local approved use can be cited. The TxGNN model predicts it may be effective for Alopecia Areata, and the evidence pack returned 18 clinical trial records and 20 publications on this drug–disease pair — though only a subset (mostly cohort studies, one systematic review, and one Phase 4 trial) directly involve methylprednisolone in alopecia areata; several of the trial hits are unrelated studies (e.g., systemic lupus erythematosus drug trials) surfaced by broad disease-term matching rather than genuine evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no ARTG-approved indication text available; drug not currently marketed in Australia) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for methylprednisolone was not available in this evidence pack (flagged as a High-severity data gap). Based on the drug’s known pharmacological identity, methylprednisolone is a systemic glucocorticoid with anti-inflammatory and immunosuppressive activity.
According to the evidence pack’s own repurposing rationale: IV or oral methylprednisolone pulse therapy is thought to act by suppressing the autoimmune inflammatory response around the hair follicle (T-cell–mediated follicular attack), thereby promoting hair regrowth. This is already an established off-label option in dermatology practice for moderate-to-severe alopecia areata, and the mechanism is supported by multiple directly relevant treatment studies (see Literature Evidence below).
Because alopecia areata is a T-cell-mediated autoimmune disease, the general immunosuppressive mechanism of glucocorticoids provides a plausible pharmacological link, distinguishing this candidate from several lower-ranked, mechanistically speculative predictions in the same evidence pack (e.g., non-inflammatory or purely genetic hair-loss disorders).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone (higher dose, more frequent pulses than standard) evaluated for safety/efficacy in severe therapy-resistant alopecia areata |
| NCT01017510 | N/A | Unknown | 20 | Compared needle-free DERMOJET vs conventional syringe for intralesional corticosteroid injection in alopecia areata; drug not explicitly confirmed as methylprednisolone (relevance grade B) |
Note: The evidence pack returned 18 clinical trial records for this drug–disease pair, but most (grade C) are unrelated trials of other drugs in systemic lupus erythematosus, surfaced by disease-term overlap rather than genuine relevance to methylprednisolone in alopecia areata. Only the two trials above were assessed as directly pertinent.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37992355 | 2023 | Review | Dermatology Practical & Conceptual | Reviews efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse therapy in alopecia areata |
| 32270396 | 2020 | Systematic Review | Dermatology and Therapy | Systematic review of cyclosporine with/without systemic corticosteroids in alopecia areata |
| 35986630 | 2022 | Retrospective Cohort | Dermatologic Therapy | Methylprednisolone alone vs methylprednisolone + methotrexate in 26 patients with extensive alopecia areata |
| 9777767 | 1998 | Open Prospective Cohort | J Am Acad Dermatol | Pulse methylprednisolone therapy in 45 patients with severe alopecia areata |
| 25566921 | 2015 | Cohort/Case Series | Indian J Dermatol Venereol Leprol | IV methylprednisolone pulse therapy in severe alopecia areata |
| 22426909 | 2012 | Cohort/Case Series | Saudi Medical Journal | Oral mega-pulse methylprednisolone for severe therapy-resistant alopecia areata |
| 21592197 | 2011 | Retrospective Cohort | J Dermatology | Prognostic factors for response to methylprednisolone pulse therapy in 70 patients with alopecia areata |
| 30745958 | 2019 | Cohort | Open Access Maced J Med Sci | Methotrexate + mini-pulse methylprednisolone in severe alopecia areata (Vietnamese cohort) |
| 18608727 | 2008 | Cohort/Combination Therapy | J Dermatolog Treat | Combination cyclosporine and methylprednisolone in severe alopecia areata |
| 36865845 | 2022 | Retrospective Cohort | Indian J Dermatol | Sex differences in response to steroid pulse therapy in alopecia areata |
Australia Market Information
No ARTG entries are currently registered for methylprednisolone in this evidence pack — market status is recorded as Not marketed in Australia, with 0 total licences. Any Australian use would currently rely on alternative marketed corticosteroid products or special access pathways; this should be confirmed directly against the TGA ARTG database before proceeding.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack does not contain usable data on key warnings, contraindications, or drug–drug interactions for methylprednisolone (all fields returned as data gaps; DDI query returned no results).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Methylprednisolone pulse therapy for alopecia areata is supported by L3-level evidence — a systematic review, several retrospective cohort studies, and one completed Phase 4 trial — consistent with its established off-label use in dermatology practice. However, the drug has no current Australian market presence and key safety documentation (TGA PI warnings/contraindications) is missing, so guardrails are warranted before clinical application.
To proceed, the following is needed:
- TGA Product Information / warnings and contraindications for methylprednisolone (currently a Blocking data gap)
- Confirmed mechanism-of-action data from DrugBank (currently a High-severity data gap)
- Verification of Australian supply pathway, since no ARTG-registered product currently exists
- A relevance re-screen of the 18 retrieved clinical trials, since most matched on disease term only and are not genuinely about methylprednisolone in alopecia areata
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.